Abbott analysers in UK false negatives alert:
This article was originally published in Clinica
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has reported problems with Abbott Diagnostics' AxSYM and AxSYM Plus laboratory analysers. Three unrepeatable false negative results have been reported at one UK centre using an HIV assay on the AxSYM Plus analyser, the agency said in an alert dated July 13. At another centre, four unrepeatable false negative results have been reported involving a rubella IgG assay on an AxSYM system. Initial investigations suggest three potential causes: a blocked process probe, unrecovered probe crashes or the wrong sample tubes.
You may also be interested in...
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.
VMS businesses are deemed essential in Department of Homeland Security guidance that provides as basis for orders by most states and localities across the US. During an AHPA webinar, attorney Trent Norris says the federal government prefers leaving business exemptions to shut-down decisions to the states.
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.